Drug Monograph
YONDELIS
Trabectedin 1mg; per vial; lyophilized pwd for IV infusion after reconstitution and dilution; contains sucrose.
Your search for Yondelis returned 106 results
News
Yondelis Approved for Advanced Soft Tissue Sarcoma
The Food and Drug Administration (FDA) has approved Yondelis (trabectedin; Janssen) for the treatment of patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline.
Slideshow
New Drug Product: Yondelis
This slideshow reviews drug information for YONDELIS (trabectedin). Click here for the complete YONDELIS new product monograph. For a downloadable PDF of this slideshow, click here.
Drugs in the Pipeline
Yondelis NDA Granted Priority Review for Soft Tissue Sarcoma
Janssen R&D and PharmaMar announced that the Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for Yondelis (trabectedin).
Drugs in the Pipeline
Pexidartinib Designated Breakthrough Therapy for Rare Tumor
The FDA has granted Breakthrough Therapy designation to pexidartinib (formerly PLX3397; Daiichi Sankyo/Plexxikon) for the treatment of tenosynovial giant cell tumor (TGCT) where surgical removal of the tumor would be associated with potentially worsening functional limitation or severe morbidity.
Drugs in the Pipeline
Eribulin vs. Dacarbazine for Soft Tissue Sarcoma: New Data Released
Eisai announced results from a Phase 3 trial investigating the use of eribulin vs. dacarbazine in patients with advanced soft tissue sarcomas.
News
Alprolix Labeling Updated With Long-Term Data, Additional Adverse Reaction
Alprolix is a recombinant clotting factor therapy developed using Fc fusion technology to prolong circulation in the body.
chart
Emetogenic Potential of Antineoplastic Agents
Emetogenic potential (high, moderate, low, or minimal risk) of oral and injectable antineoplastic agents.
News
RoxyBond, an Abuse-Deterrent Opioid Analgesic, Now Available
RoxyBond is an abuse-deterrent formulation of immediate-release oxycodone that features a unique abuse-deterrent technology.
News
RoxyBond Approved for the Management of Severe Pain
Lab tests have also shown RoxyBond to have higher resistance to cutting, crushing, grinding or breaking with selected tools when compared to another oxycodone immediate-release tablet.
